Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenomic Prediction of Antidepressant Responsiveness
NCT00817011Phase 4Unknown
- Sponsor
- Samsung Medical Center
- Start
- Apr 2006
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of antidepressant (TDDS/ODF) in major depressive disorder (MDD) (2 arms), sponsored by Samsung Medical Center. Primary endpoint: all pharmacogenetic and biological marker variables cause drug response at 24 weeks. Status: unknown.
02
Drugs
antidepressant (TDDS/ODF)
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00817011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00817011.